Trial · NCT03207750
Results by group144
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 144
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Seroprotected Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations Above or Equal to Cut-off Value. | HRV Porcine Circovirus (PCV)-Free Liquid Group | Anti-D | 478 | Participants | |
| Number of Seroprotected Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations Above or Equal to Cut-off Value. | HRV Lyophilized Group | Anti-D | 486 | Participants | |
| Number of Seroprotected Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations Above or Equal to Cut-off Value. | HRV Porcine Circovirus (PCV)-Free Liquid Group | Anti-T | 486 | Participants | |
| Number of Seroprotected Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations Above or Equal to Cut-off Value. | HRV Lyophilized Group | Anti-T | 495 | Participants | |
| Number of Seroprotected Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentrations Above or Equal to Cut-off Value. | HRV Porcine Circovirus (PCV)-Free Liquid Group | 457 | Participants | ||
| Number of Seroprotected Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentrations Above or Equal to Cut-off Value. | HRV Lyophilized Group | 471 | Participants | ||
| Number of Seroprotected Subjects With Anti-polio Virus Types 1, 2 and 3 Antibody Titers Above or Equal to Cut-off Value. | HRV Porcine Circovirus (PCV)-Free Liquid Group | Anti-Polio 1 | 477 | Participants | |
| Number of Seroprotected Subjects With Anti-polio Virus Types 1, 2 and 3 Antibody Titers Above or Equal to Cut-off Value. | HRV Lyophilized Group | Anti-Polio 1 | 486 | Participants | |
| Number of Seroprotected Subjects With Anti-polio Virus Types 1, 2 and 3 Antibody Titers Above or Equal to Cut-off Value. | HRV Porcine Circovirus (PCV)-Free Liquid Group | Anti-Polio 2 | 463 | Participants | |
| Number of Seroprotected Subjects With Anti-polio Virus Types 1, 2 and 3 Antibody Titers Above or Equal to Cut-off Value. | HRV Lyophilized Group | Anti-Polio 2 | 478 | Participants | |
| Number of Seroprotected Subjects With Anti-polio Virus Types 1, 2 and 3 Antibody Titers Above or Equal to Cut-off Value. | HRV Porcine Circovirus (PCV)-Free Liquid Group | Anti-Polio 3 | 439 | Participants | |
| Number of Seroprotected Subjects With Anti-polio Virus Types 1, 2 and 3 Antibody Titers Above or Equal to Cut-off Value. | HRV Lyophilized Group | Anti-Polio 3 | 454 | Participants | |
| Immunogenicity in Terms of Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations. | HRV Porcine Circovirus (PCV)-Free Liquid Group | Anti-PT | 51 | 95% Confidence Interval 47.8 to 54.5 | IU/mL |
| Immunogenicity in Terms of Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations. | HRV Lyophilized Group | Anti-PT | 54.2 | 95% Confidence Interval 51.3 to 57.4 | IU/mL |
| Immunogenicity in Terms of Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations. | HRV Porcine Circovirus (PCV)-Free Liquid Group | Anti-FHA | 107.3 | 95% Confidence Interval 101.4 to 113.5 | IU/mL |
| Immunogenicity in Terms of Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations. | HRV Lyophilized Group | Anti-FHA | 107.7 | 95% Confidence Interval 101.6 to 114.1 | IU/mL |
| Immunogenicity in Terms of Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations. | HRV Porcine Circovirus (PCV)-Free Liquid Group | Anti-PRN | 55 | 95% Confidence Interval 50.1 to 60.4 | IU/mL |
| Immunogenicity in Terms of Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations. | HRV Lyophilized Group | Anti-PRN | 56.6 | 95% Confidence Interval 51.9 to 61.7 | IU/mL |
| Immunogenicity in Terms of Anti-pneumococcal Serotypes (Anti-PnPS) Antibody Concentrations. | HRV Porcine Circovirus (PCV)-Free Liquid Group | Anti-PnPS 1 | 1.95 | 95% Confidence Interval 1.81 to 2.10 | µg/mL |
| Immunogenicity in Terms of Anti-pneumococcal Serotypes (Anti-PnPS) Antibody Concentrations. | HRV Lyophilized Group | Anti-PnPS 1 | 1.89 | 95% Confidence Interval 1.76 to 2.03 | µg/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03207750/results